The stock price of TRACON Pharmaceuticals is likely to experience a short-term increase as investors react positively to the update on the ENVASARC Phase 2 trial. Clinical trial updates often have a significant impact on biopharmaceutical companies' stock prices, especially when they are pivotal trials. The news directly pertains to TRACON's potential future revenues and market position, making it highly relevant and important to investors.